Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in pediatric and young adult patients with sickle cell anemia
2016-002101-19Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell anemia (SCA) and Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia) comparing canakinumab with placebo (2 arms). Primary endpoint: Reduction of average daily pain VAS from Week 8 to 12 vs baseline. Started Oct 2016; status: terminated.
02
Drugs
canakinumab
03
Conditions
sickle cell anemia (SCA)Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia)
Beyond the preview
Go deeper on 2016-002101-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002101-19.